JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB309687

Alexa Fluor® 488 Anti-Mad2L2 antibody [EPR13657]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Mad2L2/REV7 antibody - conjugated to Alexa Fluor® 488.

View Alternative Names

MAD2B, REV7, MAD2L2, Mitotic spindle assembly checkpoint protein MAD2B, Mitotic arrest deficient 2-like protein 2, REV7 homolog, MAD2-like protein 2, hREV7

  • Unconjugated

    Anti-Mad2L2/REV7 antibody [EPR13657]

  • 578 PE

    PE Anti-Mad2L2 antibody [EPR13657]

  • 660 APC

    APC Anti-Mad2L2 antibody [EPR13657]

  • HRP

    HRP Anti-Mad2L2 antibody [EPR13657]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-Mad2L2/REV7 antibody [EPR13657]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Mad2L2/REV7 antibody [EPR13657]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Mad2L2/REV7 antibody [EPR13657]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Mad2L2/REV7 antibody [EPR13657]

  • Carrier free

    Anti-Mad2L2/REV7 antibody [EPR13657] - BSA and Azide free

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Mad2L2/REV7 antibody [EPR13657]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR13657

Isotype

IgG

Conjugation

Alexa Fluor® 488

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Applications

Antibody Labelling, Target Binding Affinity

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein Mad2L2 also known as REV7 plays important roles in cellular processes. It has a molecular weight of about 26 kDa and is expressed in various tissues including the testis and placenta. Mad2L2 is an important component of the DNA damage response functioning mainly in the regulation of mitosis and repair of DNA double-strand breaks. It acts as a regulatory subunit and inhibitor of the translesion DNA synthesis (TLS) polymerase complex influencing processes linked to DNA fidelity.
Biological function summary

The protein is important for maintaining genome integrity by participating in the Fanconi anemia (FA) pathway ensuring proper DNA repair. Mad2L2 forms an important part of the homologous recombination repair system and plays a role in the recruitment of additional repair factors. It is often seen as a part of the shieldin complex which works to protect DNA ends during repair. This complex safeguarding allows it to prevent inappropriate activity during the DNA repair process.

Pathways

The involvement of Mad2L2 highlights its critical role in DNA repair mechanisms specifically homologous recombination and non-homologous end joining (NHEJ). It interacts with proteins such as 53BP1 and RIF1 within these pathways to mediate DNA repair. Such interaction is essential for choosing the correct repair pathway based on cellular needs. Mad2L2's function within the pathway guarantees the accurate resolution and repair of DNA lesions.

The protein's relevance underlines its connection to cancer and genetic disorders like Fanconi anemia. Mutations or irregularities in Mad2L2 can contribute to genomic instability leading to cancer development. In particular its interaction with the BRCA1 and BRCA2 proteins is significant; disruptions in these interactions link to increased cancer risk. This connection with tumor suppression pathways makes Mad2L2 an interesting target for therapeutic strategies in oncology.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Adapter protein able to interact with different proteins and involved in different biological processes (PubMed : 11459825, PubMed : 11459826, PubMed : 17296730, PubMed : 17719540, PubMed : 19443654, PubMed : 29656893). Mediates the interaction between the error-prone DNA polymerase zeta catalytic subunit REV3L and the inserter polymerase REV1, thereby mediating the second polymerase switching in translesion DNA synthesis (PubMed : 20164194). Translesion DNA synthesis releases the replication blockade of replicative polymerases, stalled in presence of DNA lesions (PubMed : 20164194). Component of the shieldin complex, which plays an important role in repair of DNA double-stranded breaks (DSBs) (PubMed : 29656893). During G1 and S phase of the cell cycle, the complex functions downstream of TP53BP1 to promote non-homologous end joining (NHEJ) and suppress DNA end resection (PubMed : 29656893). Mediates various NHEJ-dependent processes including immunoglobulin class-switch recombination, and fusion of unprotected telomeres (PubMed : 29656893). May also regulate another aspect of cellular response to DNA damage through regulation of the JNK-mediated phosphorylation and activation of the transcriptional activator ELK1 (PubMed : 17296730). Inhibits the FZR1- and probably CDC20-mediated activation of the anaphase promoting complex APC thereby regulating progression through the cell cycle (PubMed : 11459825, PubMed : 17719540). Regulates TCF7L2-mediated gene transcription and may play a role in epithelial-mesenchymal transdifferentiation (PubMed : 19443654).
See full target information MAD2L2
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
style
right-column

Associated Products

Select an associated product type
Alternative Version
Primary Antibodies

AB232620

Anti-Mad2L2/REV7 antibody [EPR13657] - BSA and Azide free

primary-antibodies

mad2l2-rev7-antibody-epr13657-bsa-and-azide-free-ab232620

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com